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BACKGROUND: Proteomic methods have the potential to meet the urgent need for better cancer biomarkers. We have used a range of
proteomic analyses of serum and tissue from gastric cancer patients and relevant controls to discover biomarkers for gastric cancer.
METHODS: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to
compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer
patients and 29 patients with benign gastric diseases. Expression differences were confirmed by enzyme-linked immunosorbent assay.
RESULTS: Tissue analysis shows human neutrophil peptides 1–3 (HNPs 1–3) elevated 10-fold (P¼0.001) in gastric cancer relative to
adjacent normal mucosa. Macrophage migration inhibitory factor (MIF) was increased five-fold (P¼1.84 10
 7) in the serum of
gastric cancer patients relative to individuals with benign gastric disease. The large increase in MIF concentration in serum gives an area
under the receiver operating characteristic curve of 0.85.
CONCLUSIONS: Proteomic analyses of serum and tissue indicate that HNPs 1–3 and MIF have potential as biomarkers for gastric
cancer. In particular MIF may be useful, either alone or in combination with other markers, for diagnosing and monitoring gastric
cancer.
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Gastric cancer is the fourth most common cancer and the second
leading cause of cancer-related death worldwide, surpassed only by
lung cancer (Alberts et al, 2003; Kobayashi et al, 2004). Typically,
gastric cancer is diagnosed at an advanced stage. Outcome
depends on tumour stage at the time of diagnosis, with localised
disease showing 62% 5-year survival, decreasing to 22% after
spread to regional lymph nodes and to 3% with distant organ
metastases (Jemal et al, 2007). Endoscopic examination is the most
reliable method for the diagnosis of gastric cancer. Endoscopic
screening is practiced widely in Japan because of the high
incidence rate of gastric cancer but the feasibility and cost-
effectiveness of this invasive approach in most countries remain
questionable because of the lower incidence rates (Genta, 2004).
A simple diagnostic test, such as a serum biomarker assay might
facilitate screening for gastric cancer.
Currently, there are no serum biomarkers that are sufficiently
sensitive and specific for routine diagnosis of gastric cancer
(Marrelli et al, 1999, 2001; Gaspar et al, 2001; Ishigami et al, 2001).
Although the combination of Helicobacter pylori serology and
serum pepsinogen levels helps to identify a subgroup of
individuals at higher risk for developing cancer (Varis et al,
2000; Bodger et al, 2001), it fails to differentiate tumour patients
from non-tumour controls (Miki et al, 2003). The sensitivities of
tumour markers such as CEA, CA 19–9 and CA 72–4 are low
(20–30%) (Japanese Gastric Cancer Association, 1998; Gaspar
et al, 2001; Ishigami et al, 2001; Marrelli et al, 2001).
Proteomic approaches can characterise hundreds–thousands of
proteins in clinical samples and reveal novel alterations in protein
structure or abundance with biomarker potential. It is hypothe-
sised that tumours leak, shed and secrete proteins into the
bloodstream, but the effects of dilution, expression in non-tumour
tissues and the masking effect of abundant serum proteins make
detection difficult. One approach that may overcome such
limitations is to examine both serum and tissue by detecting and
identifying differentially expressed proteins in tissue (using mass
spectrometry-based approaches) and then quantifying these in
serum with antibody-based tests.
In the experiments reported here, we use both surface-enhanced
laser desorption/ionisation time-of flight mass spectrometry
(SELDI) and antibody array analyses of tumour tissue homo-
genates and serum to identify novel biomarkers for gastric cancer.
SELDI combines on-chip retentate chromatography with mass
spectrometry to generate ‘proteomic profiles’ and can be applied to
fluids, such as serum, plasma and urine and tissue extracts (e.g.,
Rogers et al, 2003; Albrethsen et al, 2005; Ward et al, 2006, 2008;
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sBrozkova et al, 2008). SELDI provides a wealth of information on
the low molecular proteome (o20kDa), which contains diagnostic
information (Villanueva et al, 2006). We now use this technique to
analyse paired tissue and serum from gastric cancer patients and
find that SELDI detects clear differences in protein levels between
gastric tumours and normal mucosa. Three of the elevated SELDI
peaks were identified as human neutrophil peptides 1–3 (HNPs
1—3). Antibody arrays detect macrophage migration inhibitory
factor (MIF) as elevated in the serum of gastric cancer patients. We
have assayed HNPs and MIF by enzyme-linked immunosorbent
assay (ELISA) in tissue and serum to assess their potential as
gastric cancer biomarkers.
MATERIALS AND METHODS
Sample collection
Samples were collected prospectively from October 2007 to March
2008, specifically for this project, from patients attending the Mie
University Hospital and the Toyama Hospital in Japan. All patients
gave informed consent for donating blood and tissue, and the
study procedure was approved by the Institutional Review Board
of the Mie University and the Toyama Hospital of Japan.
Gastric cancer tissue samples and matched adjacent normal
gastric mucosa (n¼21) were obtained after surgical resection,
snap frozen in liquid nitrogen and stored at  801C. The tumour/
normal status of the tissue samples used for protein extraction was
verified histologically. Most tumours were classified as pT2 and
pT3. The 21 gastric cancer tissue samples were classified into
various pathological stages according to the criteria of the Japanese
Research Society for Gastric Cancer (Japanese Gastric Cancer
Association, 1998) (Table 1).
Sera were obtained from 51 gastric cancer patients (Table 1).
The control group comprised of 29 patients with gastritis or gastric
ulcers diagnosed at endoscopy. All blood samples were collected in
a fasting state in the early morning before surgery or medical
treatment. Blood was allowed to clot at room temperature for 1–
2h, centrifuged at 3000g for 20min and the serum collected and
stored at  801C until processing.
Preparation of tissue samples
Tissue samples were homogenised on ice in 100mlo f8 M
urea þ2% CHAPS containing protease inhibitor cocktail (Roche
Diagnostics, Mannheim, Germany). The tissue homogenates were
centrifuged at 12000g for 15min to remove particulate material
and stored at  801C until use. The protein concentrations of the
supernatants were determined using the Pierce BCA Protein Assay
Kit (Thermo Fisher Scientific, Loughborough, UK) calibrated with
bovine serum albumin.
SELDI
All samples were analysed in duplicate on CM10 and Cu
2þ-loaded
IMAC ProteinChip arrays using a PBS IIc time-of-flight mass
spectrometer equipped with an autoloader (Ciphergen Biosystems
Inc., Fremont, CA, USA). Serum samples were initially diluted
15-fold and tissue extracts to 1.5mg protein per ml in 8 M urea
þ1% CHAPS. These diluted samples were further diluted 1:10
(serum) or 1:5 (tissue) in binding buffer (CM10: 0.1 M sodium
acetate, pH 4.0, IMAC: 0.5 M NaCl, 0.1 M sodium phosphate, pH 7.0)
and 100ml applied to the ProteinChip arrays. After 30min
incubation the chips were washed with binding buffer, rinsed
with deionised water, air-dried and 1ml of 50% saturated sinapinic
acid in 50% acetonitrile, 0.5% trifluoroacetic acid applied twice.
Spectra were collected over m/z 0–20000 and 0–200000 ranges.
Spectra were normalised to total ion current and baselines
subtracted using Ciphergen ProteinChip software version 3.1
(Ciphergen Biosystems, Inc, Fremont, CA, USA). Peaks were
detected and clustered using Biomarker Wizard software (default
settings except for a requirement for a peak to be detected in more
than 5% of the samples) (Ciphergen Biosystems Inc).
Antibody arrays
The Panorama Antibody Microarray-XPRESS Profiler 725 kit
(Sigma-Aldrich, Saint Louis, MO, USA) was used to compare
pooled gastric cancer tissue extract (containing tissue extracts
from 17 individuals, stages II–IV) and pooled normal gastric
mucosa extract from the same 17 individuals. The experiment was
conducted according to the manufacturer’s instructions. Image
acquisition and analysis was performed using an Axon GenePix
4000B laser scanner and GenePix 5.0 software package (Axon
Instruments, Foster City, CA, USA). Background subtracted data
were normalised to the median of a set of housekeeping genes
using BRB-ArrayTools from the NCI, Bethesda, MD, USA (http://
linus.nci.nih.gov/BRB-ArrayTools.html). Log2 ratios of the same
antibody on two dye-swapped microarrays were averaged to
eliminate dye effects.
The Proteome Profiler Human Cytokine Array Panel A (R&D
Systems, Minneapolis, MN, USA) was used to compare pooled sera
from 10 non-cancer controls, 10 patients with stage I and II gastric
cancer and 10 patients with stage III and IV gastric cancer.
Analysis of 200ml of each pool was carried out according to the
manufacturer’s instructions. Images were captured on X-ray films
and digitised using a BioRad GC710 scanner. Spot intensities
were then compared using PDQuest software (BioRad, Hemel
Hempstead, UK).
Identification of SELDI peaks with biomarker potential
Polypeptides were purified by anion exchange chromatography
and reverse-phase high-performance liquid chromatography
Table 1 Demographic and clinical features of patients from whom tissue and serum samples were collected
Tissue samples Serum samples
Age (mean, range) 71.1, 58–81 years Gastric cancer (n¼51)
Male/female 16/5 Age (mean, range) 65.9, 37–87 years
Stage I 4 Male/female 41/10
Stage II 1 Stage I 25
Stage III 4 Stage II 7
Stage IV 12 Stage III 4
Stage IV 15
H. pylori (mean, range) 41.3, 5.0–138.4
Gastric ulcer/gastritis (n¼29)
Age (mean, range) 40.0, 22–69 years
Male/female (n) 17/12
H. pylori (mean, range) (Uml
 1) 23.4, 4.7–133.4
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s(HPLC) monitored by SELDI as described earlier (Ward et al,
2006). The HPLC fractions containing the polypeptides of interest
were lyophilised, reduced with dithiothreitol (DTT), alkylated with
iodoacetamide and subjected to LC-MS/MS analysis using a
75mm 10cm C8 column (New objective Woburn, MA, USA)
and a 40min gradient from 0 to 40% acetonitrile for peptide
separation and a ThermoFinnigan LTQ-FT (Thermo Scientific
Waltham, MA, USA) mass spectrometer. The CID MS/MS data
were searched against the NCBI human database using Sequest
within the Bioworks Browser software package (version 3.3.1;
Thermo Scientific Waltham, MA, USA) using ‘no enzyme’. For all
identifications, the precursor ion mass was within 10p.p.m. of the
predicted mass and the probability of an incorrect database match
was o0.05.
Quantitation of H. pylori IgG, CEA, HNPs 1–3 and MIF
The concentrations of H. pylori IgG, CEA, HNPs 1–3 and MIF were
measured in duplicate by sandwich ELISA (H. pylori IgG;
Demeditec Diagnostics GmbH, Keil-Wellsee, Germany, CEA;
Fujirebio Diagnostics, Go ¨teborg, Sweden, HNPs 1–3; Hycult
Biotechnology, Uden, The Netherlands, MIF; R&D Systems)
according to the manufacturer’s instruction.
HNPs 1–3 immunohistochemistry
Paraffin-embedded sections (5mm) of gastric cancer tissue and
adjacent normal gastric epithelium were deparaffinised and
dehydrated. The sections were microwaved in 10mmoll
 1 citric
acid, pH 6.0, to inhibit endogenous peroxidase activity, rinsed
twice with tris buffered saline (TBS), pH 7.6, and incubated
overnight at 41C in a humidity chamber with monoclonal antibody
against HNPs 1–3 (T-1034; BMA Biomedicals; Augst, Switzerland
1:200 dilution). The tissue slices were then incubated with
biotinylated goat antimouse immunoglobin followed by streptavi-
din-HRP. Finally, the sections were developed with diaminobenzi-
dene-hydrogen peroxidase substrate (DAB; Dako Corporation
Carpinteria, CA, USA), and lightly counterstained with haematox-
ylin.
Statistical analysis
Wilcoxon tests, multiple regression analysis and generation of
receiver operating characteristic (ROC) curves were performed
using R (http://www.rproject.org). Paired Wilcoxon tests were used
to analyse the tissue data and unpaired Wilcoxon tests to analyse
the serum data. In addition, multiple regression analysis linear
modelling (LM) was used to analyse the serum data to identify
proteomic features significantly associated with cancer rather than
age, gender or H. pylori level. For each proteomic feature, a linear
model was fitted where intensity was explained by tumour status,
age, gender and H. pylori IgG level. For each putative marker, ROC
curves were generated to evaluate their discriminatory power.
Partial least squares (PLS) regression was performed using
PLS_Toolbox (Version 3.5, Eigenvector Research, Manson, WA,
USA) running in Matlab (Version 7.1, The MathWorks, Natick,
MA, USA).
RESULTS
Tissue proteomics
The SELDI spectra of the tissue extracts contained 255 peaks (132
on IMAC30 and 123 on CM10). Comparison of SELDI spectra of 21
gastric cancer tissue extracts with paired adjacent normal mucosa
showed a total of 115 differentially expressed protein peaks
(Po0.05). A total of 65 peaks were upregulated in gastric cancer,
whereas 50 were downregulated. The 10 most significant peaks are
shown in Table 2. This data can be used to distinguish between
gastric cancer and normal gastric mucosa as demonstrated by the
PLS analysis shown in Figure 1.
A distinctive triplet of peaks were among the most significantly
elevated peaks in the SELDI spectra of tumour tissue using both
CM10 (m/z 3374, 3446 and 3490) and IMAC (m/z 3375, 3447 and
3492) ProteinChip arrays. A triplet of peaks with m/z values of
3372, 3443 and 3486, which bind to IMAC ProteinChip arrays, has
previously been identified as HNPs 1–3 (Albrethsen et al, 2005). It
seemed highly likely that our differentially expressed peaks also
corresponded to HNPs 1–3 and this was confirmed by purification
and LC-MS/MS of the intact polypeptides (Supplementary
information, Figure S1 and Table S1).
We used immunohistochemistry to confirm the overexpression
of HNPs 1–3 in gastric tumours and to determine the site of
expression. Human neutrophil peptides 1–3 expression was
examined in gastric cancer tissues and adjacent normal tissue
from five patients. In all cases, the normal gastric epithelium was
negative for HNPs 1–3, whereas the tumour cells showed strong
immunoreactivity, as shown in Figure 2.
Pooled gastric cancer tissue extract from 17 individuals and
pooled normal gastric mucosa extract (from the same individuals)
Table 2 The 10 most significantly cancer associated SELDI peaks in the
tissue analysis
Peak P-value (Wilcoxon’s test) Intensity ratio (C/N)
CM10 mz 2491 4.77 10
 6 0.166
IMAC mz 7475 6.68 10
 6 0.278
IMAC mz 3375* 9.54 10
 6 2.164
CM10 mz 4039 1.81 10
 5 0.176
IMAC mz 3447* 2.38 10
 5 1.998
CM10 mz 5836 2.38 10
 5 3.006
CM10 mz 3446* 3.15 10
 5 2.962
CM10 mz 2380 3.15 10
 5 0.184
IMAC mz 2515 4.10 10
 5 0.254
CM10 mz 6563 4.10 10
 5 2.596
For each peak, we show the P-value (Wilcoxon’s test) and the ratio of the median
peak height in cancer patients divided by the median peak height in non-cancer
controls. The peaks marked with asterisks are HNP 1 (molecular weight¼3448) and
HNP 2 (molecular weight¼3377).
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PLS plot of tissue SELDI data
Figure 1 Partial least squares regression analysis using all SELDI peaks
from 21 pairs of tumour/non-tumour tissue (CM10 and IMAC data).
Tumour tissue is indicated by filled symbols and normal mucosa by hollow
symbols.
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swere analysed using an antibody microarray containing 725
different antibodies representing families of proteins known to
be involved in a variety of different biological pathways. We found
small changes in the levels of 24 proteins: 17 upregulated (1.5–2-
fold) and 7 downregulated (o0.7) in cancer (Table 3).
Serum proteomics
The SELDI spectra of serum contained 228 peaks (130 on IMAC, 98
on CM10). Partial least squares using all of the peaks can
distinguish the serum of cancer and non-cancer patients (Figure 3).
In addition to Wilcoxon tests, we used LM to investigate possible
confounding factors. A total of 39 proteomic features were
significantly associated with cancer in both statistical tests
(Po0.05), but not significantly associated with age, gender or
H. pylori IgG in LM (P40.05). The 10 most significant peaks are
shown in Table 4. We have used LC-MS/MS to identify three of the
peaks that are substantially elevated in gastric cancer patients
as fragments of inter-alpha-trypsin inhibitor heavy chain 4
(ITIH4). The MS/MS identifications are shown in ‘Supplementary
information, Figure S2 and Table S1’. The IMAC peak at m/z 3030
corresponds to the peptide FRPGVLSSRQLGLPGPPDVPDHAAYH
PF, the IMAC peak at m/z 3291 corresponds to M*NFRPGVL
SSRQLGLPGPPDVPDHAAYHPF and the peak detected at m/z
4299 on IMAC chips and m/z 4303 on CM10 chips corresponds
to NVHSAGAAGSRM*NFRPGVLSSRQLGLPGPPDVPDHAAYHPF
(*denotes methionine oxidation).
Pooled serum from 10 individuals without cancer, early-stage
gastric cancer (10 individuals, stages I–II) and late-stage gastric
cancer (10 individuals, stages III–IV) were analysed using an array
of antibodies to 36 cytokines. Most of the cytokines measured did
not vary substantially between the three pooled samples, but the
levels of MIF in this semi-quantitative assay were B2-fold
increased in early-stage gastric cancer and B4-fold in late-stage
gastric cancer compared with the control pool (Figure 4).
ELISA of candidate biomarkers
To confirm the SELDI data, HNPs 1–3 levels were determined by
ELISA. The concentration of HNPs 1–3 in gastric cancer tissue was
Figure 2 Human neutrophil peptides 1–3 expression in gastric epithelial cells. Immunostaining demonstrated negative expression in normal mucosa (A)
and strong cytoplasmic expression in cancerous mucosa (B). Original magnification:  400.
Table 3 Proteins showing greater than 1.5-fold or less than 0.7-fold altered expression in tumour tissue relative to adjacent normal tissue on the
Panorama array
Antibody Gene symbols Function Ratio (C/N)
Proliferating cell nuclear antigen PCNA Gene regulation and expression 1.91
Heat-shock factor 1 HSF1 Cell stress 1.86
BACH1 BRIP1 Gene regulation and expression 1.8
BAD BAD Apoptosis 1.79
Nitric oxide synthase, brain (b-NOS) NOS1 Neurodegenerative diseases 1.71
MAP1 (Light chain) Map1lc3a Neuronal development 1.7
Tropomyosin TPM1 Cytoskeleton 1.69
NG2 Cspg4 Neuronal development 1.65
Transforming growth factor-?, pan TGFB3, TGFB1, TGFB2 Kinase/phosphatase biology 1.62
Cytokeratin 8.12 KRT15, KRT16, KRT13 Cytoskeleton 1.6
Calmodulin Calm1 Intracellular calcium signalling 1.59
Rad17 (C-terminal) RAD17 Cell cycle 1.57
Importin-a3 KPNA4 Gene regulation and expression 1.56
MBD1 MBD1 Gene regulation and expression 1.56
MRP2 ABCC2 Multidrug resistance 1.54
MBNL 1 MBNL1 Gene regulation and expression 1.53
Rab9 RAB9 G proteins and cyclic nucleotides 1.53
F1A FEM1B Apoptosis 0.66
PUMA/bbc3, C-terminal BBC3 Cell cycle 0.66
DR5 TNFRSF10B Apoptosis 0.65
PID/MTA2 MTA2 Gene regulation and expression 0.64
p53DINP1/SIP TP53INP1 Cell cycle 0.64
MAP kinase 2 (ERK-2) MAPK1 Kinase/phosphatase biology 0.6
p53R2l RRM2B Cell cycle 0.6
‘Function’ was provided by Sigma-Aldrich and gives an indication of the role of each protein. The experiment was conducted using pooled tissue extracts as described in the
Materials and Methods section.
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ssignificantly higher than in adjacent normal gastric mucosa
(median fold change¼9.79; P¼0.001, paired Wilcoxon’s test)
(Figure 5A). In the serum samples, the median concentration of
HNPs 1–3 in gastric cancer patients was also higher than in
controls (139 vs 108pgml
 1), although this trend did not reach
statistical significance (P¼0.057, Wilcoxon’s test) (Figure 5B). LM
analysis produced P-values much greater than 0.05 for any possible
associations between the serum level of HNPs 1–3 and age, gender
or H. pylori.
The median concentration of MIF in gastric cancer patients’
serum was 1933pgml
 1 compared with 414pgml
 1 for the non-
cancer controls (P¼1.84 10
 7, Wilcoxon’s test) (Figure 5D). The
tissue concentration of MIF, as determined by ELISA, was also
elevated in gastric cancer tissue than in adjacent normal gastric
mucosa (median fold change¼1.33), although not statistically
significant (P¼0.082, paired Wilcoxon’s test) (Figure 5C). As with
HNPs 1–3, LM analysis indicated that serum MIF is not
significantly influenced by gender, age or H. pylori.
Assessment of biomarker potential
Receiver operating characteristic curves for the discrimination
between gastric cancer patients and the non-cancer controls were
constructed based on serum levels of CEA, HNPs 1–3 and MIF
(Figure 6). The areas under the ROC curves were 0.57, 0.63 and
0.85. At a threshold of 800 pgml
 1, MIF correctly detects 31 out of
51 cancers (61% sensitivity) and all non-cancers (100% specifi-
city). Combining CEA and HNPs 1–3 with MIF did not
substantially increase the area under the ROC curve (data not
shown).
DISCUSSION
Proteomic analyses of serum and tissue samples from patients with
gastric cancer and appropriate controls have shown HNPs 1–3 and
MIF as elevated in gastric cancer. Human neutrophil peptides 1–3
are substantially elevated in gastric cancer tissue (as shown by
SELDI tissue analysis and confirmed by ELISA and ELISA)
and MIF is substantially elevated in the serum of gastric
cancer patients (as shown by antibody array analysis
of serum and confirmed by ELISA). We also found a number of
SELDI peaks that differed significantly between the serum of
cancer patients and controls and four of the peaks substantially
elevated in gastric cancer have been identified as fragments of
ITIH4. Interestingly, these and other fragments of ITIH4 have
previously been found to be up or downregulated in the serum of
patients with various cancers and this is believed to arise from
disease associated alterations in protease activity (Koomen et al,
2005; Song et al, 2006; Villanueva et al, 2006). A commercially
available high-density antibody microarray was used to analyse
tissue protein levels (Table 3), but did not detect any proteins
where the expression differences exceeded two-fold.
Human neutrophil peptides 1–3 are members of the a-defensin
family of antimicrobial peptides reported to be expressed by
neutrophils and epithelial cells under certain conditions (Cunliffe
et al, 2002). Human neutrophil peptides 1–3 have been shown to
be elevated in either tumour tissue or serum from patients with a
range of cancer types (Mu ¨ller et al, 2002; Lundy et al, 2004;
Albrethsen et al, 2005; Melle et al, 2005), and we now extend this
observation to gastric cancer. Human neutrophil peptides 1–3 are
also elevated by inflammation, for example, inflammatory bowel
disease (Cunliffe et al, 2002) and so may lack specificity as tumour
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Figure 3 Partial least squares regression analysis using all peaks from
CM10 and IMAC SELDI serum profiles of 50 gastric cancer patients (filled
symbols) and 29 non-cancer controls (hollow symbols).
Table 4 The 10 most significant cancer-associated SELDI peaks in the
serum analysis
Peak P-value (Wilcoxon’s test) Ratio (C/N) ROC area
CM10 mz 6679 3.50 10
 8 0.704 0.873
CM10 mz 4303# 3.92 10
 8 5.759 0.872
IMAC mz 9632 2.41 10
 7 0.682 0.849
IMAC mz 3030# 3.69 10
 7 6.139 0.844
IMAC mz 133000 1.04 10
 6 0.614 0.830
IMAC mz 3291# 1.34 10
 6 8.355 0.827
IMAC mz 4299# 2.31 10
 6 7.655 0.819
IMAC mz 6629 2.43 10
 6 0.685 0.819
IMAC mz 3956 2.43 10
 6 4.266 0.819
IMAC mz 9705 2.68 10
 6 0.698 0.817
We present P-value for cancer vs non-cancer (Wilcoxon’s test), cancer median peak
height divided by non-cancer median peak height and area under the ROC curve. All
of these peaks were also significant by LM and were not significantly associated with
age, gender or H. pylori (P40.05). Peaks arising from fragments of ITIH4 are marked
with #.
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Figure 4 The images of the duplicate MIF antibody spots on the
cytokine array for pooled control serum, pooled early (stages I–II) and
pooled late (stages III–IV) sera. The quantification of the spot intensities is
shown in the histograms.
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Figure 5 Panels A and B show the tissue and serum levels of HNPs 1–3, respectively, and panels C and D the tissue and serum levels of MIF,
respectively. Data is plotted in log10 scale. The bar near the middle of the box represents the median value. The bottom and top of the box represent the
lower and upper quartiles, respectively.
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Figure 6 Receiver operator characteristic curves for CEA (A), HNPs 1–3 (B) and MIF (C). Curves for cancer vs control are shown as solid lines, early
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smarkers. Melle et al (Melle et al, 2005) have presented data
suggesting that the HNPs 1–3 are overexpressed by tumour cells in
colon cancer, but Lundy et al (2004) reported abundant HNPs 1–3
in infiltrating neutrophils in oral cancer consistent with HNPs 1–3
playing a role in innate host defence against the tumour. We have
used immunohistochemistry to localise the expression of HNPs
1–3 in gastric tissues. The data shown in Figure 2 clearly indicate
that the source of elevated HNPs 1–3 in gastric cancers is
expression by the epithelial cells of the tumours rather than by
infiltrating neutrophils.
Overexpression of MIF has been reported in prostate, breast,
colon and hepatocellular carcinomas (Akbar et al, 2001; Meyer-
Siegler et al, 2002; Lee et al, 2008; Xu et al, 2008). In 2006 He et al.
(He et al, 2006) reported MIF overexpression in the tissue and
serum of gastric cancer patients from Hong Kong. More recently
Camlica et al. (Camlica et al, 2008) reported elevated serum MIF in
gastric cancer patients relative to healthy controls. We now report
that this is also the case in patients from Japan, a country with one
of the highest incidences of gastric cancer in the world (Parkin
et al, 2005), and add to the body of evidence that MIF may be a
useful biomarker for gastric cancer. Furthermore, our data suggest
that serum MIF is elevated in the early stages of gastric cancer
relative to relevant disease control subjects, a factor that is of
considerable importance in establishing a useful diagnostic role for
this potential biomarker. In agreement with the findings of He et al
(2006), we find that tissue and serum levels of MIF are not strongly
influenced by H. pylori.
Macrophage migration inhibitory factor is a pro-inflammatory
cytokine, which is able to promote tumour cell proliferation,
migration and metastasis and tumour angiogenesis (Wilson et al,
2005; Xu et al, 2008). Mechanisms involved include activation of
the MAP kinase pathways through CD74 and CD44 (Shi et al,
2006), suppression of p53 (Hudson et al, 1999; Fingerle-Rowson
et al, 2003) and downregulation of NKG2D enhancing immune
evasion by cancer cells (Krockenberger et al, 2008). As with HNPs
1–3, MIF may lack specificity for gastric cancer as it has been
reported as elevated in the plasma of patients with ulcerative colitis
and Crohn’s disease (de Jong et al, 2001; Murakami et al, 2001).
However, preliminary work in our laboratory suggests a degree of
disease specificity: serum MIF is also elevated in European patients
with hepatocellular carcinoma (relative to our 29 Japanese non-
cancer controls), but is not elevated in patients with lung or
pancreas cancer or individuals without cancer (n X 30 per group,
data not shown).
In conclusion, our proteomic analyses of tissue and serum from
gastric cancer patients have shown MIF, HNPs 1–3 and fragments
of ITIH4 as potential biomarkers for gastric cancer. In particular,
serum MIF is highly elevated in the potentially curable early stages
of gastric cancer thus warranting further studies to validate this
candidate biomarker as a blood test for gastric cancer, either on its
own or as part of a panel of biomarkers.
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